Saturday 17 October 2026
Export ATRA’s income statement to Excel — free account
Atara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
9.18
0.47
−4.87%
Follow ATRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
6.46 | 5.72 | 0.00 | 0.00 |
P/S ratio |
1.28 | 1.88 | 2.88 | 27.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.86) | (39.83) | (21.67) | (51.70) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.19 | 1.81 | 2.52 | 26.27 | |
EV/EBITDA |
6.15 | 5.71 | 0.00 | 0.00 | |
EV/Operating CF |
(2.59) | (4.29) | (2.25) | (7.43) | |
EV/FCF |
(2.60) | (4.36) | (2.33) | (7.73) | |
Quick Ratio |
0.87 | 0.65 | 1.48 | 1.49 | |
Current Ratio |
1.02 | 0.82 | 2.16 | 1.98 | |
Net Debt/EBITDA |
3.79 | 3.49 | 2.50 | 2.09 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.76 | 1.87 | 0.56 | 0.21 | |
Operating CF/Net income |
2.27 | 1.67 | 0.74 | 0.69 | |
Capex/Depreciation |
(0.94) | 4.17 | 0.00 | 0.00 | |
Interest Coverage |
(3.93) | (2.87) | (4.06) | (24.71) | |
Research and Development Expense of Revenue |
84.71% | (13.98%) | 31.78% | 213.49% | |
Selling, General and Administrative Expense of Revenue |
115.46% | 268.15% | 697.09% | 605.40% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
35.48% | 95.11% | 145.16% | 62.54% | |
Graham Net Nets |
(0.25) | (0.20) | (0.68) | (0.26) | |
Graham Number |
0.00 | 0.00 | 6.27 | 8.08 | |
Earnings Yield |
15.49% | 17.47% | (13.95%) | (10.28%) | |
Free Cash Flow Yield |
(35.71%) | (22.07%) | (37.56%) | (12.19%) | |
Revenue per Share |
0.25 | 0.13 | 0.04 | 0.04 | |
Operating CF per Share |
(0.72) | (0.45) | (0.22) | (0.22) | |
Capex per Share |
0.00 | 0.04 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.72) | (0.41) | (0.22) | (0.22) | |
Cash per Share |
1.01 | 0.68 | 0.59 | 0.66 | |
Shareholders Equity per Share |
(2.70) | (3.07) | (2.65) | (2.46) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.70) | (3.07) | (2.65) | (2.46) | |
Free Cash Flow |
(9.74) | (5.14) | (3.07) | (3.34) | |
Working Capital |
0.38 | (2.71) | 6.53 | 6.68 | |
Capital Expenditures |
0.04 | 0.56 | — | — | |
Net Current Asset Value |
(48.37) | (46.52) | (45.14) | (44.49) | |
EV/EBIT |
6.89 | 6.09 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | (0.35) | 0.00 | 0.00 | |
Price to Operating Income |
7.41 | 6.33 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.17 | 1.29 | — | 0.90 | |
Average Payables |
1.23 | 2.25 | 1.01 | 1.29 | |
Average Assets |
86.44 | 64.67 | 41.02 | 28.96 | |
Average Common Equity |
(63.59) | (67.89) | (46.19) | (36.02) |
Columns are period end dates